EVEXTA-BIO
19.6.2024 17:08:31 CEST | Business Wire | Press release
Evexta Bio SA, a clinical-stage biotechnology company focused on developing first-in-class therapies in oncology, announces the appointment of Shawn M. Leland, PharmD, RPh as Chairman of the Board of Directors.
Shawn is an accomplished pharmaceutical and biotechnology professional with more than 15 years of experience in the industry. Throughout his career, Shawn has successfully advanced novel oncology assets and programs, raised substantial capital for various ventures, negotiated major global licensing agreements, and established strategic partnerships. His extensive experience in leading biotech startups, raising capital and executing strategic collaborations will be a major benefit to Evexta Bio in its growth and corporate development strategy.
Most recently, Shawn was the Interim CEO and Board Director of ForeBio, where he led the company through a phase 2 study with registrational intent and closed a $75M Series D financing.
In July 2019, Shawn founded Elevation Oncology, where he served as Chief Business Officer and Board Director, and later as CEO until January 2023. During his mandate, the company advanced multiple novel targeted oncology assets. Shawn raised over $200M in capital, which included a $100M IPO. Shawn grew Elevation Oncology from zero to more than 50 employees.
Shawn was Head of Business Development at Verastem Oncology from 2017 – 2019 and Argos Therapeutics from 2013 – 2017 where he played a pivotal role in each company’s corporate development strategy leading multiple partnerships and licensing transactions. Shawn started his career with pharmaceutical and biotechnology companies, ARIAD Pharmaceuticals and Eli Lilly. Shawn holds a PharmD from Albany College of Pharmacy.
Alain Chevallier, former Chairman of the board of Directors of Evexta Bio, said: “I'm pleased to be handing over the chairmanship to a great professional of the oncology and biotech field as Shawn, who brings new valuable perspectives to Evexta Bio, and I will continue, as Vice-Chairman, to be fully committed to the success of the Company.”
Scott Filosi, CEO of Evexta Bio added: “I am delighted to welcome Shawn as Chairman of the Board of Directors. His experience and expertise in oncology and strategic development of biotechnology companies are real assets for Evexta Bio. I’m looking forward to working with him to accelerate the mission of Evexta Bio.”
Shawn M. Leland, Chairman of the Board of Directors of Evexta Bio, said: "I’m looking forward to joining the team of Evexta Bio in such a pivotal moment of its development. Evexta Bio has tremendous potential and I thank the members of the Board of Directors for their trust.”
About Evexta Bio (https://www.evextabio.com)
Evexta Bio is a biopharmaceutical company exploring the new frontiers of oncology in search of daring novel therapeutic approaches with the potential to save lives. Now, in the clinic, the company is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications:
- Rupitasertib, an optimized S6K inhibitor with efficient AKT1/AKT3 control of compensatory AKT feed-back loop. The oral anti-tumor agent is expected to enter phase 2 clinical trial in ESR1mt ER+ HER2- advanced breast cancer.
- EVX020, a sole-in-class KIF20A kinesin inhibitor having shown potent nonclinical efficacy in hematological and solid tumor models. Two strategies are under assessment, development of EVX020 as a prodrug and as a payload for antibody-drug conjugate (ADC).
Founded by Truffle Capital, supported by Merck KGaA (Darmstadt, Germany) as shareholder, Evexta Bio has forged alliances with leaders in academia and industry, including CNRS, Paoli-Calmettes Institute (Marseille, France) and Merck KGaA. The company is supported by seasoned management team, board of directors and medical advisory board.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240619024966/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IAMPHENOM Europe 2026 Registration Opens: HR’s Leading Conference for Agentic AI Learning Returns20.5.2026 13:00:00 CEST | Press release
Europe’s CHROs, CIOs and HRIT Leaders Head to Paris for Learning How AI Redesigns Work Operations Across Hiring, Development and Retention Phenom, the leader in applied AI with an infrastructure built specifically to redesign work operations, today announced registration is open for IAMPHENOM Europe 2026, taking place 4-5 November in Paris, France. The only applied AI event dedicated to human resources on the continent, IAMPHENOM Europe gives HR and HRIT leaders the agentic AI strategies, instruction and proof points they need to build their AI-augmented workforce to address their biggest hiring, development and retention challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520683492/en/ Phenom today announced registration is open for IAMPHENOM Europe 2026. The only applied AI event dedicated to human resources on the continent is taking place 4-5 November in Paris, France. European organisations face pressure from
BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard20.5.2026 12:00:00 CEST | Press release
Campaign connects the preparation, precision, and grit that define great goalkeeping to the persistent scientific, clinical, and community efforts that drive progress in cancer careFeatures international goalkeepers, uniting soccer’s global reach with BeOne’s commitment to patients everywhere BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today launched One Save Changes Everything, a campaign that uses soccer as a lens to recognize the scientific, clinical, and human moments that matter in cancer care. The campaign launches with goalkeeping legends, including former U.S. Men’s National Team goalkeeper Tim Howard. The initiative is backed by a $300,000 community commitment for the installation of soccer mini-pitches near cancer treatment centers with the U.S. Soccer Foundation, and BeOne colleague‑driven charitable support across the world. This press release features multimedia. View the full release here: https://www.businesswire.com
Chiesi Group Announces New Chair and Vice Chair20.5.2026 11:00:00 CEST | Press release
Highlights:Planned transition in the Chair and Vice Chair roles reflects the Chiesi family’s long-term commitment to continuity, shared value and responsible governance across generationsMaria Paola Chiesi is appointed Chair, the first woman in this role; aims to reinforce sustainability as an integral and enduring pillar of the Group’s strategy Chiesi today announced a planned leadership change in its Board of Directors: Maria Paola Chiesi has been appointed Chair of the Board, succeeding Alessandro Chiesi, who is completing his tenure after nearly three years in the role, and will now continue to serve as Vice Chair. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520447292/en/ Maria Paola Chiesi is appointed Chair of Chiesi Board of Directors, the first woman in this role; aims to reinforce sustainability as an integral and enduring pillar of the Group’s strategy During his mandate, Alessandro Chiesi oversaw the Group t
Insurance Investment Outsourcing Surpasses $5.5 Trillion as Private Markets and Global Expansion Reshape the Industry20.5.2026 09:00:00 CEST | Press release
IIOR Shows Record Outsourced Insurance AUM, Private Assets Near $1 Trillion, and Europe Emerging as a Global Growth Engine Clearwater Analytics (NYSE: CWAN) today released the 2026 Insurance Investment Outsourcing Report (IIOR), produced in partnership with DCS Financial Consulting. The report captures $5.5 trillion in third-party general account insurance assets under management across 96 asset managers, a 23% increase year-over-year and a 65% increase since 2021, alongside $1.8 trillion in assets under advisement across 12 investment consultants. The findings point to an outsourcing market that has become larger, more global, and materially more complex. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520780028/en/ The 2026 IIOR reveals defining trends reshaping insurance investment management: Private Markets Cross a Threshold. Third-party private insurance AUM has more than doubled since 2021, reaching $947 billion and
Factbird Adds Quality & Compliance and Reports to its Manufacturing Intelligence Platform20.5.2026 08:00:00 CEST | Press release
Two new capabilities give multi-site manufacturers standardized workflows, traceable records, and automated reporting across every plant. Today, Factbird is announcing two major additions to its manufacturing intelligence platform: Quality & Compliance and Factbird Reports. Both address a problem that compounds as manufacturers grow. More sites mean more variation in how work gets done. More regulation means more documentation pressure on frontline teams. And more data, when fragmented across systems, often slows decisions rather than speeding them up. Solving this has traditionally meant large IT projects and months of deployment. “Enterprise manufacturers shouldn’t have to choose between capability and simplicity,” said Mogens Arne Hansen, Chief Technology and Product Officerat Factbird. “With Quality & Compliance and Reports, you can have standardized, audit-ready operations and automated performance reporting across every site, deployed in days, used by the people on the floor.” Qu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom